Enliven Therapeutics, Inc.
NASDAQEnliven Therapeutics heads into July with analyst conviction rising sharply on one side and a quiet but steady rebuild in short positioning on the other — a split that makes the setup more charged than the stock's modest weekly gain suggests. The analyst story is the standout this week. Stifel raised its price target to $80 on July 1 — up from $60, against a current price of $50.75…
ELVN cost to borrow surges to 1.22%, up 127% in one week, as availability plummets to 1,812% of short interest.
Snapshot as of 19 Jul 2026
Enliven Therapeutics heads into July with analyst conviction rising sharply on one side and a quiet but steady rebuild in short positioning on the other — a split that makes the setup more charged than the stock's…
Enliven Therapeutics enters its June 9 earnings call in an uncomfortable spot: the stock has shed 16.5% over the past week and 15% over the past month, closing at $35.52, while Wall Street has just sharply lifted its…
Enliven Therapeutics heads into its May 11 earnings release carrying the fingerprints of a short-side exodus — but options traders remain more defensively positioned than usual. Short sellers have been quietly exiting.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ELVN — free to start on ORTEX.
Sign up for free →Open ELVN on ORTEX